1
|
Corianò M, Tommasi C, Dinh ATL, Needham J, Aziz H, Joharatnam-Hogan N, Cunningham N, Waterhouse J, Sun M, Turkes F, Pellegrino B, McGrath S, Okines A, Parton M, Turner N, Johnston S, Musolino A, Ring A, Battisti NML. The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study. Breast Cancer Res Treat 2024:10.1007/s10549-024-07336-4. [PMID: 38743174 DOI: 10.1007/s10549-024-07336-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2024] [Accepted: 04/10/2024] [Indexed: 05/16/2024]
Abstract
PURPOSE Many patients with early breast cancer (eBC) undergoing neoadjuvant chemotherapy do not achieve pathological complete response (pCR), which is a prognostic factor. We examined the role of HER2-low expression in predicting pCR and prognosis in HER2-negative eBC. METHODS We evaluated patients with stage I-III HER2-negative BC, treated between 2013 and 2023 at The Royal Marsden NHS Foundation Trust, London. Tumors were classified based on estrogen receptor (ER) status and into HER2-low and HER2-zero subgroups. We analyzed pCR rates, relapse-free survival (RFS) and overall survival (OS). RESULTS 754 patients were included in the analysis. pCR rate was 8.9% in the ER+ /HER2-low, 16.5% in the ER+ /HER2-zero, 38.9% in the ER- ER-/HER2-low and 35.9% in the ER-/HER2-zero eBC (p < 0.001). Multivariable analysis showed a significantly lower pCR rate in HER2-low compared to HER2-zero BC in the ER+ subgroup. At a median follow-up of 63.8 months (59.9-67.4), we observed longer OS in HER2-low compared to HER2-zero patients in the overall and in the ER+ population. There was no predictive or prognostic impact of HER2-low status in the ER- population. CONCLUSION This study supports the interpretation of HER2 status as a possible prognostic and predictive biomarker for HER2-negative eBC, especially among patients with ER+ disease.
Collapse
Affiliation(s)
- Matilde Corianò
- Department of Medicine and Surgery, Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy
- Breast Unit - Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK
| | - Chiara Tommasi
- Department of Medicine and Surgery, Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy
| | - Anh Thi Lan Dinh
- Breast Unit - Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK
- Vietnam National Cancer Hospital, Hanoi, Vietnam
| | - Jazmine Needham
- Breast Unit - Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK
| | - Hala Aziz
- Breast Unit - Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK
| | | | - Niamh Cunningham
- Breast Unit - Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK
| | - Jasmin Waterhouse
- Breast Unit - Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK
| | - Mingze Sun
- Breast Unit - Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK
- University College London Medical School, London, UK
| | - Fiona Turkes
- Breast Unit - Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK
| | - Benedetta Pellegrino
- Department of Medicine and Surgery, Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy
| | - Sophie McGrath
- Breast Unit - Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK
| | - Alicia Okines
- Breast Unit - Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK
| | - Marina Parton
- Breast Unit - Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK
| | - Nicholas Turner
- Breast Unit - Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK
| | - Stephen Johnston
- Breast Unit - Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK
| | - Antonino Musolino
- Department of Medicine and Surgery, Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy
| | - Alistair Ring
- Breast Unit - Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK
| | | |
Collapse
|
2
|
Cartwright E, Slater S, Saffery C, Tran A, Turkes F, Smith G, Aresu M, Kohoutova D, Terlizzo M, Zhitkov O, Rana I, Johnston EW, Sanna I, Smyth E, Mansoor W, Fribbens C, Rao S, Chau I, Starling N, Cunningham D. Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma: EMERGE. ESMO Open 2024; 9:102971. [PMID: 38518549 PMCID: PMC10972804 DOI: 10.1016/j.esmoop.2024.102971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Revised: 02/23/2024] [Accepted: 02/26/2024] [Indexed: 03/24/2024] Open
Abstract
BACKGROUND Most oesophagogastric adenocarcinomas (OGAs) and colorectal cancers (CRCs) are mismatch repair proficient (MMRp), responding poorly to immune checkpoint inhibition. We evaluated the safety and efficacy of domatinostat (histone deacetylase inhibitor) plus avelumab (anti-PD-L1 antibody) in patients with previously treated inoperable, advanced/metastatic MMRp OGA and CRC. PATIENTS AND METHODS Eligible patients were evaluated in a multicentre, open-label dose escalation/dose expansion phase II trial. In the escalation phase, patients received escalating doses of domatinostat [100 mg once daily (OD), 200 mg OD, 200 mg twice daily (BD)] orally for 14 days followed by continuous dosing plus avelumab 10 mg/kg administered intravenously 2-weekly (2qw) to determine the recommended phase II dose (RP2D). The trial expansion phase evaluated the best objective response rate (ORR) during 6 months by RECIST version 1.1 using a Simon two-stage optimal design with 2/9 and 1/10 responses required to proceed to stage 2 in the OGA and CRC cohorts, respectively. RESULTS Patients (n = 40) were registered between February 2019 and October 2021. Patients in the dose escalation phase (n = 12) were evaluated to confirm the RP2D of domatinostat 200 mg BD plus avelumab 10 mg/kg. No dose-limiting toxicities were observed. Twenty-one patients were treated at the RP2D, 19 (9 OGA and 10 CRC) were assessable for the best ORR; 2 patients with CRC did not receive combination treatment and were not assessable for the primary endpoint analysis. Six patients were evaluated in the dose escalation and expansion phases. In the OGA cohort, the best ORR was 22.2% (95% one-sided confidence interval lower bound 4.1) and the median duration of disease control was 11.3 months (range 9.9-12.7 months). No responses were observed in the CRC cohort. No treatment-related grade 3-4 adverse events were reported at the RP2D. CONCLUSIONS Responses in the OGA cohort met the criteria to expand to stage 2 of recruitment with an acceptable safety profile. There was insufficient signal in the CRC cohort to progress to stage 2. TRIAL REGISTRATION NCT03812796 (registered 23rd January 2019).
Collapse
Affiliation(s)
- E Cartwright
- Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London
| | - S Slater
- Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London
| | - C Saffery
- Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London
| | - A Tran
- Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London
| | - F Turkes
- Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London
| | - G Smith
- Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London
| | - M Aresu
- Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London
| | - D Kohoutova
- Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London
| | - M Terlizzo
- Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London
| | - O Zhitkov
- Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London
| | - I Rana
- Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London
| | - E W Johnston
- Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London
| | - I Sanna
- Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London
| | - E Smyth
- Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London
| | - W Mansoor
- Oesophago-Gastric Cancer Services, The Christie NHS Foundation Trust, Manchester, UK
| | - C Fribbens
- Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London
| | - S Rao
- Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London
| | - I Chau
- Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London
| | - N Starling
- Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London
| | - D Cunningham
- Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital NHS Foundation Trust, London.
| |
Collapse
|
3
|
Slater S, Cartwright E, Saffery C, Tran A, Smith G, Bacason M, Zhitkov O, Rana I, Johnston E, Sanna I, Aresu M, Kohoutova D, Terlizzo M, Turkes F, Smyth E, Mansoor W, Fribbens C, Rao S, Watkins D, Starling N, Chau I, Cunningham D. PD-2 EMERGE: A multi-centre, non-randomised, single-arm phase II study investigating domatinostat plus avelumab in patients with previously treated advanced mismatch repair-proficient oesophagogastric and colorectal adenocarcinoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
4
|
Turkes F, Bryant A, Begum R, Davidson M, Kalaitzaki E, Aresu M, Lazaro-Alcausi R, Bryant J, Rana I, Chua S, Aronson L, Hulkki-Wilson S, Fribbens C, Watkins D, Rao S, Starling N, Cunningham D, Chong IY, Chau I. Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study. Curr Oncol 2022; 29:2174-2184. [PMID: 35448150 PMCID: PMC9029374 DOI: 10.3390/curroncol29040176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Revised: 03/02/2022] [Accepted: 03/14/2022] [Indexed: 11/24/2022] Open
Abstract
Oesophagogastric (OG) cancer is a highly lethal disease requiring novel treatment options. c-MYC and/or HER-2 amplified oesophageal cancer models have demonstrated sensitivity to BTK inhibition with ibrutinib. We evaluated the safety and efficacy of ibrutinib in patients with c-MYC and/or HER2 amplified pre-treated advanced OG cancer. c-MYC and HER2 amplification status were determined by FISH. The primary endpoint was overall response rate (ORR). Secondary endpoints were disease control rate (DC) at 8 weeks, safety, progression-free survival (PFS) and overall survival (OS). Eleven patients were enrolled. Eight patients had c-MYC amplified tumours, six were HER2 amplified and three were c-MYC and HER2 co-amplified. Grade ≥ 3 adverse events were fever, neutropenia, and vomiting. Grade ≥ 3 gastrointestinal haemorrhage occurred in three patients and was fatal in two cases. Among seven evaluable patients, three patients (43%) achieved a best response of SD at 8 weeks. No PR or CR was observed. Disease control was achieved for 32 weeks in one patient with a dual c-MYC and HER2 highly co-amplified tumour. The median PFS and OS were 1.5 (95% CI: 0.8–5.1) and 5.1 (95% CI: 0.8–14.5) months, respectively. Ibrutinib had limited clinical efficacy in patients with c-MYC and/or HER2 amplified OG cancer. Unexpected gastrointestinal bleeding was observed in 3 out of 8 treated patients which was considered a new safety finding for ibrutinib in this population.
Collapse
Affiliation(s)
- Fiona Turkes
- Royal Marsden NHS Foundation Trust, Downs Road, Surrey SM2 5PT, UK; (F.T.); (A.B.); (R.B.); (M.D.); (E.K.); (M.A.); (R.L.-A.); (J.B.); (I.R.); (S.C.); (S.H.-W.); (C.F.); (D.W.); (S.R.); (N.S.); (D.C.)
| | - Annette Bryant
- Royal Marsden NHS Foundation Trust, Downs Road, Surrey SM2 5PT, UK; (F.T.); (A.B.); (R.B.); (M.D.); (E.K.); (M.A.); (R.L.-A.); (J.B.); (I.R.); (S.C.); (S.H.-W.); (C.F.); (D.W.); (S.R.); (N.S.); (D.C.)
| | - Ruwaida Begum
- Royal Marsden NHS Foundation Trust, Downs Road, Surrey SM2 5PT, UK; (F.T.); (A.B.); (R.B.); (M.D.); (E.K.); (M.A.); (R.L.-A.); (J.B.); (I.R.); (S.C.); (S.H.-W.); (C.F.); (D.W.); (S.R.); (N.S.); (D.C.)
| | - Michael Davidson
- Royal Marsden NHS Foundation Trust, Downs Road, Surrey SM2 5PT, UK; (F.T.); (A.B.); (R.B.); (M.D.); (E.K.); (M.A.); (R.L.-A.); (J.B.); (I.R.); (S.C.); (S.H.-W.); (C.F.); (D.W.); (S.R.); (N.S.); (D.C.)
| | - Eleftheria Kalaitzaki
- Royal Marsden NHS Foundation Trust, Downs Road, Surrey SM2 5PT, UK; (F.T.); (A.B.); (R.B.); (M.D.); (E.K.); (M.A.); (R.L.-A.); (J.B.); (I.R.); (S.C.); (S.H.-W.); (C.F.); (D.W.); (S.R.); (N.S.); (D.C.)
| | - Maria Aresu
- Royal Marsden NHS Foundation Trust, Downs Road, Surrey SM2 5PT, UK; (F.T.); (A.B.); (R.B.); (M.D.); (E.K.); (M.A.); (R.L.-A.); (J.B.); (I.R.); (S.C.); (S.H.-W.); (C.F.); (D.W.); (S.R.); (N.S.); (D.C.)
| | - Retchel Lazaro-Alcausi
- Royal Marsden NHS Foundation Trust, Downs Road, Surrey SM2 5PT, UK; (F.T.); (A.B.); (R.B.); (M.D.); (E.K.); (M.A.); (R.L.-A.); (J.B.); (I.R.); (S.C.); (S.H.-W.); (C.F.); (D.W.); (S.R.); (N.S.); (D.C.)
| | - Jane Bryant
- Royal Marsden NHS Foundation Trust, Downs Road, Surrey SM2 5PT, UK; (F.T.); (A.B.); (R.B.); (M.D.); (E.K.); (M.A.); (R.L.-A.); (J.B.); (I.R.); (S.C.); (S.H.-W.); (C.F.); (D.W.); (S.R.); (N.S.); (D.C.)
| | - Isma Rana
- Royal Marsden NHS Foundation Trust, Downs Road, Surrey SM2 5PT, UK; (F.T.); (A.B.); (R.B.); (M.D.); (E.K.); (M.A.); (R.L.-A.); (J.B.); (I.R.); (S.C.); (S.H.-W.); (C.F.); (D.W.); (S.R.); (N.S.); (D.C.)
| | - Sue Chua
- Royal Marsden NHS Foundation Trust, Downs Road, Surrey SM2 5PT, UK; (F.T.); (A.B.); (R.B.); (M.D.); (E.K.); (M.A.); (R.L.-A.); (J.B.); (I.R.); (S.C.); (S.H.-W.); (C.F.); (D.W.); (S.R.); (N.S.); (D.C.)
| | - Lauren Aronson
- Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK; (L.A.); (I.Y.C.)
| | - Sanna Hulkki-Wilson
- Royal Marsden NHS Foundation Trust, Downs Road, Surrey SM2 5PT, UK; (F.T.); (A.B.); (R.B.); (M.D.); (E.K.); (M.A.); (R.L.-A.); (J.B.); (I.R.); (S.C.); (S.H.-W.); (C.F.); (D.W.); (S.R.); (N.S.); (D.C.)
| | - Charlotte Fribbens
- Royal Marsden NHS Foundation Trust, Downs Road, Surrey SM2 5PT, UK; (F.T.); (A.B.); (R.B.); (M.D.); (E.K.); (M.A.); (R.L.-A.); (J.B.); (I.R.); (S.C.); (S.H.-W.); (C.F.); (D.W.); (S.R.); (N.S.); (D.C.)
| | - David Watkins
- Royal Marsden NHS Foundation Trust, Downs Road, Surrey SM2 5PT, UK; (F.T.); (A.B.); (R.B.); (M.D.); (E.K.); (M.A.); (R.L.-A.); (J.B.); (I.R.); (S.C.); (S.H.-W.); (C.F.); (D.W.); (S.R.); (N.S.); (D.C.)
| | - Sheela Rao
- Royal Marsden NHS Foundation Trust, Downs Road, Surrey SM2 5PT, UK; (F.T.); (A.B.); (R.B.); (M.D.); (E.K.); (M.A.); (R.L.-A.); (J.B.); (I.R.); (S.C.); (S.H.-W.); (C.F.); (D.W.); (S.R.); (N.S.); (D.C.)
| | - Naureen Starling
- Royal Marsden NHS Foundation Trust, Downs Road, Surrey SM2 5PT, UK; (F.T.); (A.B.); (R.B.); (M.D.); (E.K.); (M.A.); (R.L.-A.); (J.B.); (I.R.); (S.C.); (S.H.-W.); (C.F.); (D.W.); (S.R.); (N.S.); (D.C.)
| | - David Cunningham
- Royal Marsden NHS Foundation Trust, Downs Road, Surrey SM2 5PT, UK; (F.T.); (A.B.); (R.B.); (M.D.); (E.K.); (M.A.); (R.L.-A.); (J.B.); (I.R.); (S.C.); (S.H.-W.); (C.F.); (D.W.); (S.R.); (N.S.); (D.C.)
| | - Irene Y. Chong
- Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK; (L.A.); (I.Y.C.)
| | - Ian Chau
- Royal Marsden NHS Foundation Trust, Downs Road, Surrey SM2 5PT, UK; (F.T.); (A.B.); (R.B.); (M.D.); (E.K.); (M.A.); (R.L.-A.); (J.B.); (I.R.); (S.C.); (S.H.-W.); (C.F.); (D.W.); (S.R.); (N.S.); (D.C.)
- Correspondence:
| |
Collapse
|
5
|
Cartwright E, Turkes F, Saffery C, Tran A, Smith G, Moreno SE, Hatt S, Renn A, Johnston E, Kohoutova D, Begum R, Smyth E, Peckitt C, Fribbens C, Rao S, Watkins D, Chau I, Starling N, Cunningham D. 443P EMERGE: A phase II trial assessing the efficacy of domatinostat plus avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal cancers – phase IIA dose finding. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.964] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
6
|
Abstract
Gastrointestinal (GI) cancers are among the most common and lethal solid tumors worldwide. Unlike in malignancies such as lung, renal and skin cancers, the activity of immunotherapeutic agents in GI cancers has, on the whole, been much less remarkable and do not apply to the majority. Furthermore, while incremental progress has been made and approvals for use of immune checkpoint inhibitors (ICIs) in specific subsets of patients with GI cancers are coming through, in a population of 'all-comers', it is frequently unclear as to who may benefit most due to the relative lack of reliable predictive biomarkers. For most patients with newly diagnosed advanced or metastatic GI cancer, the mainstay of treatment still involves chemotherapy and/or a targeted agent however, beyond the second-line this paradigm confers minimal patient benefit. Thus, current research efforts are concentrating on broadening the applicability of ICIs in GI cancers by combining them with agents designed to beneficially remodel the tumor microenvironment (TME) for more effective anti-cancer immunity with intention of improving patient outcomes. This review will discuss the currently approved ICIs available for the treatment of GI cancers, the strategies underway focusing on combining ICIs with agents that target the TME and touch on recent progress toward identification of predictors of sensitivity to immune checkpoint blockade in GI cancers.
Collapse
Affiliation(s)
- Fiona Turkes
- Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - Justin Mencel
- Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - Naureen Starling
- Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, London, UK.
| |
Collapse
|
7
|
Turkes F, Carmichael J, Cunningham D, Starling N. Contemporary Tailored Oncology Treatment of Biliary Tract Cancers. Gastroenterol Res Pract 2019; 2019:7698786. [PMID: 31929787 PMCID: PMC6935796 DOI: 10.1155/2019/7698786] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2019] [Accepted: 09/05/2019] [Indexed: 02/06/2023] Open
Abstract
Biliary tract cancers (BTCs) are poor prognosis malignancies with limited treatment options. Capecitabine has recently emerged as an effective agent in the adjuvant setting; however, treatment of advanced disease is still limited to first-line cisplatin and gemcitabine chemotherapy. Recent global efforts in genomic profiling and molecular subtyping of BTCs have uncovered a wealth of genomic aberrations which may carry prognostic significance and/or predict response to treatment, and several targeted agents have shown promising results in clinical trials. As such, the uptake of comprehensive genomic profiling for patients with BTCs and the expansion of basket trials to include these patients are growing. This review describes the currently approved systemic therapies for BTCs and provides insight into the emerging targeted and immunotherapeutic agents, as well as conventional chemotherapeutic regimes, currently being investigated in clinical trials.
Collapse
Affiliation(s)
- Fiona Turkes
- Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - Juliet Carmichael
- Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - David Cunningham
- Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - Naureen Starling
- Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, London, UK
| |
Collapse
|
8
|
Cartwright E, Turkes F, Saffery C, Kalaitzaki E, Powell R, Wotherspoon A, De Paepe K, von Loga K, Hubank M, Rao S, Watkins D, Chau I, Starling N, Cunningham D. EMERGE: Epigenetic modulation of the immune response in gastrointestinal cancers. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.147] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Davidson M, Butler C, Butters O, Fong C, Turkes F, Cafferkey C, Kouvelakis K, Cunningham D, Watkins D, Rao S, Starling N, Chau I. Treatment of relapsed oesophagogastric adenocarcinoma after perioperative chemotherapy and surgery. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Irfan T, Turkes F, Asare B, Mohammed K, Osin P, Nerurkar A, Smith I, Parton M, Johnston S, Turner N, Okines A. Clinical Outcomes in Triple-negative Lobular Breast Cancer: a Single-institution Experience. Clin Oncol (R Coll Radiol) 2019. [DOI: 10.1016/j.clon.2019.03.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
11
|
Abstract
Ramucirumab is a fully humanized monoclonal antibody directed selectively at VEGFR-2 - a key player in the VEGF orchestra and angiogenic process. It has demonstrated clinical efficacy and a favorable safety profile in the treatment of a number of malignancies including gastric, lung, urothelial, colorectal and, most recently, advanced liver cancer. This article describes the recent Phase III trial results of ramucirumab in patients with hepatocellular carcinoma, including safety data and patient-reported outcomes, with particular emphasis on efficacy data in the patient population with baseline α-fetoprotein levels ≥400 ng/ml, traditionally considered a poor prognostic group.
Collapse
Affiliation(s)
- Fiona Turkes
- Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - Ian Chau
- Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, London, UK
| |
Collapse
|
12
|
Kumar R, Brandao M, Joharatnam N, Pealing J, Walder D, Minchom A, Milner-Watts C, Moorcraft S, Turkes F, Yousaf N, Bhosle J, Popat S, O’Brien M. P2.07-049 Early Clinical Predictors of Progressive Disease or Non-Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
13
|
Turkes F, Murphy E, Land J, Demiray B, Duberley K, Briddon A, Hargreaves I. Assessment of mitochondrial electron transport chain function in a primary astrocyte cell model of hyperhomocystinaemia. Toxicol Mech Methods 2013; 23:459-63. [DOI: 10.3109/15376516.2013.780276] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|